tradingkey.logo
tradingkey.logo
Suchen

Harvard Bioscience Inc

HBIO
Zur Watchlist hinzufügen
6.050USD
-0.100-1.63%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
27.29MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Harvard Bioscience Inc Unternehmen

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Harvard Bioscience Inc Informationen

BörsenkürzelHBIO
Name des UnternehmensHarvard Bioscience Inc
IPO-datumOct 21, 2013
CEODuke (John D)
Anzahl der mitarbeiter330
WertpapierartOrdinary Share
GeschäftsjahresendeOct 21
Addresse84 October Hill Rd
StadtHOLLISTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01746-1371
Telefon15088938999
Websitehttps://www.harvardbioscience.com/
BörsenkürzelHBIO
IPO-datumOct 21, 2013
CEODuke (John D)

Führungskräfte von Harvard Bioscience Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Harvard Bioscience Inc?

Die fünf größten Anteilseigner von Harvard Bioscience Inc sind: Ms. Katherine Anne Eade, J.D.

Wie viele Institutionen halten Anteile an Harvard Bioscience Inc (HBIO)?

Mit Stand vom 2026Q1 halten 201 Institutionen Anteile an Harvard Bioscience Inc, mit einem Gesamtmarktwert von etwa 2.44M, was 54.17% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -447956.00 gestiegen.

Was ist die größte Einnahmequelle von Harvard Bioscience Inc?

Am 2026Q1 erzielte das Geschäft mit Instruments, equipment, software and accessories für Harvard Bioscience Inc den höchsten Umsatz in Höhe von 78.26M, was 90.42% des Gesamtumsatzes entspricht.